Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Brest Cancer × eribulin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 62 Triple Negative Breast Neoplasms 13 Neoplasm Metastasis 8 Sarcoma 6 Brain Neoplasms 4 Ovarian Neoplasms 3 Neoplasms 3 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Leiomyosarcoma 2 HER2-negative Breast Cancer 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Salivary Gland Neoplasms 1 Relapsed Solid Tumors 1 Refractory Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Metastatic Urothelial Cell Cancer 1 Lymphoma 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HER2-negative Metastatic Breast Cancer 1 HER-2 Positive Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1

Interventions

eribulin 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07333937 2026-01-12

NETHER

Xijing Hospital

Phase 2 Not yet recruiting

Brest Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡